Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8683 · 1 trial · 1 indication
Maximum FEV1 value
Trough FEV1 value
| Arm | Type | Description |
|---|---|---|
| First 50 mcg, then 200 mcg, then placebo | EXPERIMENTAL | period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo |
| First 50 mcg, then placebo, then 200 mcg | EXPERIMENTAL | period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg |
| First 200 mcg, then placebo, then 50 mcg | EXPERIMENTAL | period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg |
| First 200 mcg, then 50 mcg, then placebo | EXPERIMENTAL | period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo |
| First placebo, then 200 mcg, then 50 mcg | EXPERIMENTAL | period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg |
| First placebo, then 50 mcg, then 200 mcg | EXPERIMENTAL | period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg |
| Name | Type | Description |
|---|---|---|
| AZD8683, 50 mcg | DRUG | Dry powder for inhalation, single dose |
| Placebo | DRUG | Dry powder for inhalation, single dose |
| AZD8683, 200 mcg | DRUG | Dry powder for inhalation, single dose |
Inclusion Criteria: * Clinical diagnosis of COPD * Current or ex-smokers * FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator FEV1/FVC \< 70% Exclusion Criteria: * Any clinically significant disease or disorder * Any clinically relevant abnormal findings at ...
AZD8683 is an investigational inhaled small molecule developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It was studied in a Phase 2 clinical trial in patients with COPD. AZD8683 has not been approved for any indication and remains an investigational therapy in clinical development.
AZD8683 targets CHRM3, the muscarinic acetylcholine receptor M3, and acts as an antagonist at this receptor. By blocking CHRM3, the drug is designed to interfere with cholinergic signaling in the airways, a mechanism relevant to the management of Chronic Obstructive Pulmonary Disease (COPD).
AZD8683 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 2 study of AZD8683 in patients with Chronic Obstructive Pulmonary Disease (COPD).
AZD8683 is in Phase 2 development. It has completed one Phase 2 clinical trial in patients with Chronic Obstructive Pulmonary Disease (COPD). AZD8683 is investigational and has not been approved by the FDA or any other regulatory agency for commercial use.
AZD8683 has been evaluated in one completed Phase 2 trial, NCT01205269, titled a study to evaluate the effect of AZD8683 in patients with Chronic Obstructive Pulmonary Disease (COPD). The trial enrolled 28 patients in Poland, was randomized, double blind, and controlled, and included participants aged 40 years and older.